136 related articles for article (PubMed ID: 29116379)
21. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer.
Stinchcombe TE; Harper HD; Hensing TA; Moore DT; Crane JM; Atkins JN; Willard EM; Detterbeck FC; Socinski MA
J Thorac Oncol; 2008 Feb; 3(2):145-51. PubMed ID: 18303435
[TBL] [Abstract][Full Text] [Related]
22. Platinum-Based Adjuvant Chemotherapy for Stage II and Stage III Squamous Cell Carcinoma of the Lung.
Isaka T; Nakayama H; Yokose T; Ito H; Katayama K; Yamada K; Masuda M
Ann Thorac Cardiovasc Surg; 2017 Feb; 23(1):19-25. PubMed ID: 28025447
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
24. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
[TBL] [Abstract][Full Text] [Related]
25. Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.
Wislez M; Barlesi F; Besse B; Mazières J; Merle P; Cadranel J; Audigier-Valette C; Moro-Sibilot D; Gautier-Felizot L; Goupil F; Renault A; Quoix E; Souquet PJ; Madroszyck A; Corre R; Pérol D; Morin F; Zalcman G; Soria JC
J Clin Oncol; 2014 Apr; 32(12):1256-61. PubMed ID: 24638013
[TBL] [Abstract][Full Text] [Related]
26. [A retrospective study of the efficacy and toxicity of irinotecan in combination with nedaplatin versus irinotecan in combination with cisplatin as salvage
treatment in refractory or relapsed small cell lung cancer].
Yu S; Wang Y; Hu X; Wang H; Hao X; Xu J; Li J; Zhang X; Shi Y
Zhongguo Fei Ai Za Zhi; 2013 Sep; 16(9):470-5. PubMed ID: 24034994
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer.
Li C; Huang XE; Li Y
Asian Pac J Cancer Prev; 2011; 12(2):487-90. PubMed ID: 21545218
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY
Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659
[TBL] [Abstract][Full Text] [Related]
29. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
30. Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
Kiura K; Takigawa N; Segawa Y; Tabata M; Shibayama T; Gemba K; Bessho A; Fujimoto N; Takata I; Hotta K; Fujiwara K; Tokuda Y; Kuyama S; Shinkai T; Ueoka H; Tanimoto M;
J Thorac Oncol; 2007 Jan; 2(1):44-50. PubMed ID: 17410009
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.
Ramsden K; Laskin J; Ho C
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):394-400. PubMed ID: 25800720
[TBL] [Abstract][Full Text] [Related]
32. Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer.
Hirai F; Seto T; Shimokawa M; Inamasu E; Toyozawa R; Toyokawa G; Yoshida T; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Anticancer Res; 2014 Feb; 34(2):927-31. PubMed ID: 24511034
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.
Hirose T; Sugiyama T; Kusumoto S; Shirai T; Nakashima M; Yamaoka T; Okuda K; Ogura K; Ohnishi T; Ohmori T; Adachi M
Anticancer Res; 2009 May; 29(5):1733-8. PubMed ID: 19443395
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant chemotherapy for radically resected non-small cell lung cancer: a retrospective analysis of 311 consecutively treated patients.
Dediu M; Horvat T; Tarlea A; Anghel R; Cordos I; Miron G; Iorga P; Alexandru A; Nistor C; Grozavu C; Savu C
Lung Cancer; 2005 Jan; 47(1):93-101. PubMed ID: 15603859
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non-small cell lung cancer.
Igawa S; Otani S; Nakahara Y; Ryuge S; Hiyoshi Y; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sato Y; Sasaki J; Masuda N
Invest New Drugs; 2018 Feb; 36(1):45-52. PubMed ID: 28466376
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.
Okuda K; Hirose T; Ishida H; Kusumoto S; Sugiyama T; Ando K; Shirai T; Ohnishi T; Horichi N; Ohmori T; Adachi M
Cancer Chemother Pharmacol; 2008 Apr; 61(5):829-35. PubMed ID: 17589845
[TBL] [Abstract][Full Text] [Related]
37. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.
Chang MH; Kim KH; Jun HJ; Kim HS; Yi SY; Uhm JE; Park MJ; Lim DH; Ji SH; Hwang IG; Lee J; Park YH; Ahn JS; Ahn MJ; Park K
Cancer Chemother Pharmacol; 2009 Oct; 64(5):917-24. PubMed ID: 19221753
[TBL] [Abstract][Full Text] [Related]
38. Comparison of nedaplatin and irinotecan for patients with squamous and nonsquamous cell carcinoma of the lung: meta-analysis of four trials.
Oshita F; Honda T; Murakami S; Kondo T; Saito H; Noda K; Yamada K
J Thorac Oncol; 2011 Jan; 6(1):128-31. PubMed ID: 21150472
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
40. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
